Clinicopathologic and Genomic Characterization of SMARCA4-Deficient Carcinoma of the Gallbladder
Modern Pathology · 2025
DOI: 10.1016/j.modpat.2025.100868 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2025. Verfasst von Qiqi Jia und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Transcription Factors, DNA Helicases, Gallbladder Neoplasms, Nuclear Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Institute of Genomics, Chinese Academy of Sciences, Key Research and Development Projects of Shaanxi Province.
Abstract (Originalsprache)
As a key subunit of the SWItch/sucrose nonfermentable chromatin-remodeling complex, SMARCA4 plays a critical role as a tumor suppressor in various tumors. However, the clinicopathological and molecular features of SMARCA4-deficient carcinoma of the gallbladder (SMARCA4-dGBC) have not been well explored. In this study, a retrospective cohort of 926 nonsquamous cell gallbladder carcinomas (GBCs) was analyzed on tissue microarrays using immunohistochemistry for SMARCA4, comprising 813 adenocarcinomas, 53 adenosquamous carcinomas, 43 undifferentiated carcinomas, 7 sarcomatoid carcinomas, 6 small cell neuroendocrine carcinomas, and 4 large cell neuroendocrine carcinomas. Twenty-six (2.8%) SMARCA4-dGBCs were identified and further analyzed using immunohistochemistry, whole-exome sequencing, and clinicopathological data. SMARCA4-dGBCs are frequently identified in advanced stages and exhibit diverse patterns of differentiation. The majority were identified as monotonous diffuse sheets, nests, and cords, whereas a subset exhibited gland-forming and rhabdoid morphologies (11.5%). Tumors retained mismatch repair proficiency (100%) but showed variable HER2 expression (11.5% scored as 2+/3+) and limited PD-L1 positivity. Genomic profiling revealed SMARCA4 alterations in 88.5% (23/26) of patients, predominantly deletions (91.3%) and truncating mutations-p.K892∗ and p.R979∗-that disrupt the critical ATPase/helicase domains. Co-occurring TP53 mutations (56.5%) highlighted the presence of synergistic chromatin-remodeling defects. Enrichment of oncogenic signaling pathways, including the RTK-RAS (78.3%), TP53 (60.9%), NOTCH (47.8%), and HIPPO (39.1%) pathways, was observed. Patients with SMARCA4-dGBC exhibited significantly shorter progression-free survival (median, 6 vs 14 months) and overall survival (median, 11 vs 16 months) than those with SMARCA4-retained tumors. Overall, these findings revealed that SMARCA4-dGBC is a rare, distinct entity characterized by the destabilization of the SWItch/sucrose nonfermentable complex, genomic instability, and resistance to conventional therapies. The prevalence of targetable pathways, such as RTK-RAS and cell cycle dysregulation, highlights opportunities for precise therapeutic strategies involving EZH2, CDK4/6, or ATR inhibitors. SMARCA4 immunohistochemistry and molecular profiling are essential for accurate diagnosis, prognostic stratification, and therapeutic innovation of this GBC subtype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Department of Pathology, Yulin Hospital of Traditional Chinese Medicine, Yulin, China.
- Department of Pathology, The First Affiliated Hospital of Xi'an Medical University, Xi'an, China.
- Department of Pathology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address: xliu83@xjtu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Beijing Institute of Genomics, Chinese Academy of Sciences
- Key Research and Development Projects of Shaanxi Province
- Geneseeq Technology
- Xi'an Jiaotong University
Zitieren
APA
Jia, Q., Chen, Y., Pan, Y., Gao, S., Wei, X., Fan, Y., Li, P., Yang, Z., Pu, J., Nan, P., Chang, H., Zheng, J., Zhang, G., & Liu, X. (2025). Clinicopathologic and Genomic Characterization of SMARCA4-Deficient Carcinoma of the Gallbladder. Modern Pathology. https://doi.org/10.1016/j.modpat.2025.100868
Vancouver
Jia Q, Chen Y, Pan Y, Gao S, Wei X, Fan Y, et al. Clinicopathologic and Genomic Characterization of SMARCA4-Deficient Carcinoma of the Gallbladder. Modern Pathology. 2025. doi:10.1016/j.modpat.2025.100868
BibTeX
@article{Jia2025,
author = {Jia, Qiqi and Chen, Yishan and Pan, Yuyao and Gao, Shan and Wei, Xiaoyun and Fan, Yangyang and Li, Pengjun and Yang, Zhe and Pu, Jun and Nan, Pengfei and Chang, Hongyun and Zheng, Jianyun and Zhang, Guanjun and Liu, Xi},
title = {Clinicopathologic and Genomic Characterization of SMARCA4-Deficient Carcinoma of the Gallbladder},
journal = {Modern Pathology},
year = {2025},
doi = {10.1016/j.modpat.2025.100868}
}
EUVIMED